{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:07Z","timestamp":1792786147227,"version":"4.5.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Deputyship for Research &Innovation, Ministry of Education in Saudi Arabia","award":["IF2\/PSAU\/2022\/03\/22660"],"award-info":[{"award-number":["IF2\/PSAU\/2022\/03\/22660"]}],"id":[{"id":"https:\/\/ror.org\/00q919b81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:p>Phosphodiesterase (PDE) inhibitors regulate cyclic adenosine monophosphate and cyclic guanosine monophosphate pathways, which influence neurodevelopment, cardiovascular function, and immune responses. Multiple PDE families exist, classified as dual-substrate (PDE1, PDE2, PDE3, PDE10, PDE11) or non-dual-substrate (PDE4, PDE5, PDE6, PDE7, PDE8, PDE9), each with distinct biological roles. This review summarizes the therapeutic applications of PDE inhibitors, evaluates evidence across different disease domains, and highlights challenges and future research priorities. A narrative review of published studies and clinical trial data was conducted, focusing on pharmacological properties, therapeutic relevance, and safety profiles of PDE inhibitors. Sources included PubMed, ClinicalTrials.gov, and regulatory reports. Dual-substrate PDEs demonstrate therapeutic potential in Alzheimer disease (PDE1), anxiety and memory enhancement (PDE2), and heart failure (PDE3), although chronic PDE3 inhibition may increase risks. Non-dual-substrate PDEs, such as PDE4 and PDE5, are clinically established for asthma, chronic obstructive pulmonary disease, psoriasis, erectile dysfunction, and pulmonary hypertension. Advances in structure\u2013activity relationship studies have produced more selective and potent inhibitors. However, adverse effects, such as nausea (PDE4 inhibitors) and cardiovascular risks (long-term PDE3 inhibitors), remain limiting factors. PDE inhibitors represent a rapidly evolving therapeutic class with broad clinical applications. Their further development requires strategies to minimize adverse effects, improve selectivity, and better define disease-specific roles. Future research should focus on precision medicine approaches to fully harness their therapeutic potential.<\/jats:p>","DOI":"10.1097\/md.0000000000047683","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:03:11Z","timestamp":1773043391000},"page":"e47683","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Biological implications and therapeutic potential of phosphodiesterase inhibitors: A review"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2215-8878","authenticated-orcid":false,"given":"Mansour","family":"Alnazari","sequence":"first","affiliation":[{"name":"Department of General and Specialized Surgery, College of Medicine, Taibah University, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Bakhsh","sequence":"additional","affiliation":[{"name":"Department of General and Specialized Surgery, College of Medicine, Taibah University, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-0702","authenticated-orcid":false,"given":"Sulaiman","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Department of General and Specialized Surgery, College of Medicine, Taibah University, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2419-2188","authenticated-orcid":false,"given":"Saeed","family":"Al Qahtani","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, College of Medicine, Taibah University, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2499-8189","authenticated-orcid":false,"given":"Walaa","family":"Borhan","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, College of Medicine, Taibah University, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-8248","authenticated-orcid":false,"given":"Emad","family":"Rajih","sequence":"additional","affiliation":[{"name":"Department of General and Specialized Surgery, College of Medicine, Taibah University, Madinah, Saudi Arabia"},{"name":"Department of Surgery, King Faisal Specialist Hospital & Research Center, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-2341","authenticated-orcid":false,"given":"Ahmed M.","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj, Riyadh, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrm911","article-title":"Cyclic nucleotide research\u2014still expanding after half a century.","volume":"3","author":"Beavo","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: inhibition and beyond.","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3390\/ijms23042145","article-title":"Phosphodiesterases and compartmentation of cAMP and cGMP signaling in regulation of cardiac contractility in normal and failing hearts.","volume":"23","author":"Calamera","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.2600640106","article-title":"Cyclic nucleotide phosphodiesterases: properties, activators, inhibitors, structure\u2013activity relationships, and possible role in drug development.","volume":"64","author":"Amer","year":"1975","journal-title":"J Pharm Sci"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.","volume":"76","author":"Conti","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1742-1241.2002.tb11296.x","article-title":"Pharmacology of phosphodiesterase-5 inhibitors.","volume":"56","author":"Corbin","year":"2002","journal-title":"Int J Clin Pract"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/1381612820666140826114601","article-title":"Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer\u2019s disease: a translational overview.","volume":"21","author":"Heckman","year":"2015","journal-title":"Curr Pharm Des"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/scipharm89020029","article-title":"Caesalpinia sappan L. Ameliorates scopolamine-induced memory deficits in mice via the cAMP\/PKA\/CREB\/BDNF pathway.","volume":"89","author":"Helmi","year":"2021","journal-title":"Sci Pharm"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/ph14010058","article-title":"A perspective on natural and nature-inspired small molecules targeting phosphodiesterase 9 (PDE9): chances and challenges against neurodegeneration.","volume":"14","author":"Ribaudo","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1871524922666211231115638","article-title":"Pharmacophore modelling and virtual screening studies for the discovery of potential natural products based PDE1B inhibitor lead compounds.","volume":"21","author":"Shy","year":"2021","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"107858","DOI":"10.1016\/j.pharmthera.2021.107858","article-title":"Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities.","volume":"226","author":"Samidurai","year":"2021","journal-title":"Pharmacol Ther"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1038\/s41380-020-00997-9","article-title":"Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders.","volume":"26","author":"Delhaye","year":"2021","journal-title":"Mol Psychiatry"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"35558","DOI":"10.18632\/oncotarget.16009","article-title":"cAMP\/PKA-CREB-BDNF signaling pathway in hippocampus mediates cyclooxygenase 2-induced learning\/memory deficits of rats subjected to chronic unpredictable mild stress.","volume":"8","author":"Luo","year":"2017","journal-title":"Oncotarget"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"114170","DOI":"10.1016\/j.ejmech.2022.114170","article-title":"Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer\u2019s disease.","volume":"232","author":"Xi","year":"2022","journal-title":"Eur J Med Chem"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuroscience.2011.02.042","article-title":"Corticosterone induced morphological changes of hippocampal and amygdaloid cell lines are dependent on 5-HT7 receptor related signal pathway.","volume":"182","author":"Xu","year":"2011","journal-title":"Neuroscience"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bcp.2011.11.009","article-title":"Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer\u2019s disease therapeutics.","volume":"83","author":"Scott Bitner","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.neurobiolaging.2014.08.028","article-title":"Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal remodeling caused by chronic stress.","volume":"36","author":"Xu","year":"2015","journal-title":"Neurobiol Aging"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cellsig.2017.11.004","article-title":"Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.","volume":"42","author":"Kelly","year":"2018","journal-title":"Cell Signal"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2012.06.048","article-title":"Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe\/PS1dE9 mouse model of Alzheimer\u2019s disease.","volume":"64","author":"Sierksma","year":"2013","journal-title":"Neuropharmacology"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"173768","DOI":"10.1016\/j.ejphar.2020.173768","article-title":"Phosphodiesterase-2 inhibitor reverses post-traumatic stress induced fear memory deficits and behavioral changes via cAMP\/cGMP pathway.","volume":"891","author":"Chen","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10557-007-6014-6","article-title":"Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease.","volume":"21","author":"Osadchii","year":"2007","journal-title":"Cardiovasc Drugs Ther"},{"key":"R23-20261009","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/01.RES.0000168066.06333.df","article-title":"Cardiac sarcoplasmic reticulum calcium release and load are enhanced by subcellular camp elevations in PI3Kgamma-deficient mice.","volume":"96","author":"Kerfant","year":"2005","journal-title":"Circ Res"},{"key":"R24-20261009","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tcm.2006.04.006","article-title":"Phosphoinositide 3-kinase gamma regulates cardiac contractility by locally controlling cyclic adenosine monophosphate levels.","volume":"16","author":"Kerfant","year":"2006","journal-title":"Trends Cardiovasc Med"},{"key":"R25-20261009","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCRESAHA.107.156422","article-title":"Pi3kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium atpase in cardiomyocytes.","volume":"101","author":"Kerfant","year":"2007","journal-title":"Circ Res"},{"key":"R26-20261009","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/0002-8703(91)90829-7","article-title":"Cardiovascular effects of milrinone.","volume":"121","author":"Colucci","year":"1991","journal-title":"Am Heart J"},{"key":"R27-20261009","doi-asserted-by":"crossref","first-page":"H1898","DOI":"10.1152\/ajpheart.2000.279.4.H1898","article-title":"Effect of milrinone on left ventricular relaxation and ca(2+) uptake function of cardiac sarcoplasmic reticulum.","volume":"279","author":"Yano","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R28-20261009","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrm1151","article-title":"Phospholamban: a crucial regulator of cardiac contractility.","volume":"4","author":"MacLennan","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R29-20261009","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/01.RES.0000218493.09370.8e","article-title":"A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes.","volume":"98","author":"Rochais","year":"2006","journal-title":"Circ Res"},{"key":"R30-20261009","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"R31-20261009","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10741-008-9130-x","article-title":"Phosphodiesterase inhibition in heart failure.","volume":"14","author":"Movsesian","year":"2009","journal-title":"Heart Fail Rev"},{"key":"R32-20261009","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2174\/157016109788340668","article-title":"Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies.","volume":"7","author":"Mangiafico","year":"2009","journal-title":"Curr Vasc Pharmacol"},{"key":"R33-20261009","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.cellsig.2007.03.012","article-title":"Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.","volume":"19","author":"Sun","year":"2007","journal-title":"Cell Signal"},{"key":"R34-20261009","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2004.07.017","article-title":"Pi3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects.","volume":"118","author":"Patrucco","year":"2004","journal-title":"Cell"},{"key":"R35-20261009","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1021\/acs.jmedchem.9b00518","article-title":"Structure-aided identification and optimization of tetrahydro-isoquinolines as novel PDE4 inhibitors leading to discovery of an effective antipsoriasis agent.","volume":"62","author":"Zhang","year":"2019","journal-title":"J Med Chem"},{"key":"R36-20261009","doi-asserted-by":"crossref","first-page":"113155","DOI":"10.1016\/j.ejmech.2021.113155","article-title":"Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors-an update of recent progress.","volume":"214","author":"Amin","year":"2021","journal-title":"Eur J Med Chem"},{"key":"R37-20261009","doi-asserted-by":"crossref","first-page":"115419","DOI":"10.1016\/j.molliq.2021.115419","article-title":"Computer simulation to identify selective inhibitor for human phosphodiesterase10A.","volume":"328","author":"Bhardwaj","year":"2021","journal-title":"J Mol Liq"},{"key":"R38-20261009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fendo.2016.00111","article-title":"Alterations of phosphodiesterases in adrenocortical tumors.","volume":"7","author":"Hannah-Shmouni","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R39-20261009","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0021-9258(19)77422-5","article-title":"Formation of a cyclic adenine ribonucleotide by tissue particles.","volume":"232","author":"Rall","year":"1958","journal-title":"J Biol Chem"},{"key":"R40-20261009","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0021-9258(18)60316-3","article-title":"Adenosine 3\u2032,5\u2032-phosphate in biological materials. I. Purification and properties of cyclic 3\u2032,5\u2032-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3\u2032,5\u2032-phosphate in human urine.","volume":"237","author":"Butcher","year":"1962","journal-title":"J Biol Chem"},{"key":"R41-20261009","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/cvr\/cvab008","article-title":"Physiological and pathological roles of protein kinase A in the heart.","volume":"118","author":"Liu","year":"2022","journal-title":"Cardiovasc Res"},{"key":"R42-20261009","doi-asserted-by":"crossref","first-page":"12891","DOI":"10.1073\/pnas.200355397","article-title":"Cloning and characterization of two splice variants of human phosphodiesterase 11A.","volume":"97","author":"Hetman","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R43-20261009","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1073\/pnas.97.7.3702","article-title":"Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A.","volume":"97","author":"Fawcett","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R44-20261009","doi-asserted-by":"crossref","first-page":"31469","DOI":"10.1074\/jbc.M003041200","article-title":"Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression.","volume":"275","author":"Yuasa","year":"2000","journal-title":"J Biol Chem"},{"key":"R45-20261009","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1046\/j.1432-1327.2001.02366.x","article-title":"Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A): comparison of rat and human PDE11A splicing variants.","volume":"268","author":"Yuasa","year":"2001","journal-title":"Eur J Biochem"},{"key":"R46-20261009","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ng1809","article-title":"A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia.","volume":"38","author":"Horvath","year":"2006","journal-title":"Nat Genet"},{"key":"R47-20261009","doi-asserted-by":"crossref","first-page":"E208","DOI":"10.1210\/jc.2010-1704","article-title":"Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype.","volume":"96","author":"Lib\u00e9","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R48-20261009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/17425255.2017.1244265","article-title":"Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.","volume":"13","author":"Hong","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R49-20261009","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/bio.2018.0010","article-title":"Prematuration culture with phosphodiesterase inhibitors after vitrification may induce recovery of mitochondrial activity in vitrified mouse immature oocytes.","volume":"16","author":"Yoon","year":"2018","journal-title":"Biopreserv Biobank"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:09:43Z","timestamp":1791569383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047683","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"2024-09-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}